Buscar
01/06/2025
Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG
Vicente, EC, Pease, S, Imran, N, Gandhi, K, Ait-Tihuaty, M, Turkoz, I, Coteur, G, Gary, C, Choudhry, Z, Ramchandran, S, Vissing, J. Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025
Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms
Villaverde, R, Gomez-Ballesteros, R, Reyes, V, Armangue, T, Querol, L, Gutierrez-Gutierrez, G, Sotoca, J, Ares, A, Salas, E, Abos, PD, Squaglia, A, Maurino, J, Cortes-Vicente, E. Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025
SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: SELECTED SECONDARY OUTCOMES FROM THE ADHERE TRIAL
Lewis, RA, Suresh, N, Mazzeo, A, Allen, JA, Querol, L, Hussain, YM, Gwathmey, KG, Guptill, JT, Istas, G, Van Hoorick, B, Mole, T, Kuwabara, S, Basta, I, van Door, PA. SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: SELECTED SECONDARY OUTCOMES FROM THE ADHERE TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
EFFICACY OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: PHASE 2 SUBGROUP ANALYSES
Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. EFFICACY OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: PHASE 2 SUBGROUP ANALYSES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
SAFETY AND EFFICACY OF RILIPRUBART IN CIDP 76-WEEK PHASE 2 TRIAL RESULTS
Falzone, Y, Querol, L, Lewis, R, Hartung, HP, van Doorn, P, Lin, J, Donnie, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, R. SAFETY AND EFFICACY OF RILIPRUBART IN CIDP 76-WEEK PHASE 2 TRIAL RESULTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
CHAT-GPT-4O IN DIAGNOSIS AND MANAGEMENT OF REAL-LIFE POLYNEUROPATHY CASES: COMPARATIVE ANALYSIS WITH NEUROLOGISTS
De Lorenzo, A, Moretti, GS, Bertini, A, De Lorenzo, A, Vidiella, RC, Falzone, YM, Fortanier, E, Gendre, T, Gentile, F, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mandia, D, Marion, M, Mira, V, Peric, S, Querol, L, Rajabally, Y, Sevilla, T, Tomaselli, PJ, Tozza, S, Bosca, M, Brouwer, M, Cocco, A, Cousyn, L, De Santis, T, Gonzalez, F, Lukic, MJ, Mistry, N, Maranzano, A, Morena, E, Nakano, FN, Saura, GO, Sechi, E, Ticozzi, N, Troisi, S, Tsokkos, T, Aymeric, W, Pisciotta, C, Orazio, EN, Pareyson, D, Doneddu, PE. CHAT-GPT-4O IN DIAGNOSIS AND MANAGEMENT OF REAL-LIFE POLYNEUROPATHY CASES: COMPARATIVE ANALYSIS WITH NEUROLOGISTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL
Gallo, C, Doneddu, PE, Collet-Vidiella, R, Cocito, D, Manganelli, F, Falzone, Y, Pinter, GL, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Dalla Bella, E, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS
Allen, JA, Door, PAV, Benedetti, L, Basta, I, Dysgaard, T, Eggers, C, Guptill, JT, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, TN, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).